Gisclon L G, Boyd R A, Williams R L, Giacomini K M
Department of Pharmacy, School of Pharmacy, University of California, San Francisco 94143.
Clin Pharmacol Ther. 1989 Apr;45(4):444-52. doi: 10.1038/clpt.1989.53.
It is generally assumed that the systems involved in the transport of organic cations and organic anions in the renal proximal tubule are substrate selective (i.e., organic anions do not inhibit organic cation transport and vice versa). However, recent data obtained in vitro have suggested that the organic anion probenecid inhibits the renal transport of the organic cation cimetidine. We addressed the question of whether this interaction is biologically relevant in human beings. The study involved a two-treatment, randomized crossover design. Six healthy male subjects were given an intravenous infusion of 300 mg cimetidine alone as one treatment and, as the other treatment, received multiple oral doses of probenecid before receiving the cimetidine infusion. The renal clearance of cimetidine and inulin was determined in each period. There were no significant differences between treatments in cimetidine plasma concentrations, apparent volume of distribution, systemic clearance, half-life, amount of drug excreted unchanged in the urine, or nonrenal clearance. Probenecid significantly decreased the renal clearance of cimetidine by decreasing both the filtration clearance and the net secretory clearance. These effects were most evident in the first 1/2 to 1 hour after cimetidine administration, when probenecid levels in plasma and renal tissue would have been the highest. Because there was no effect of probenecid on cimetidine plasma concentrations, this interaction is not clinically relevant to the therapeutic use of these two compounds. However, the study demonstrates that renal interactions between organic cations and organic anions can occur in human beings. The mechanism of this interaction and the implications to other drug combinations are being explored.
一般认为,肾近端小管中参与有机阳离子和有机阴离子转运的系统具有底物选择性(即有机阴离子不抑制有机阳离子转运,反之亦然)。然而,最近的体外实验数据表明,有机阴离子丙磺舒可抑制有机阳离子西咪替丁的肾脏转运。我们探讨了这种相互作用在人类中是否具有生物学相关性。该研究采用了两治疗组、随机交叉设计。六名健康男性受试者作为一种治疗,单独静脉输注300mg西咪替丁;作为另一种治疗,在接受西咪替丁输注前多次口服丙磺舒。在每个阶段测定西咪替丁和菊粉的肾清除率。在西咪替丁的血浆浓度、表观分布容积、全身清除率、半衰期、尿中未改变排泄的药物量或非肾清除率方面,各治疗组之间无显著差异。丙磺舒通过降低滤过清除率和净分泌清除率显著降低了西咪替丁的肾清除率。这些作用在西咪替丁给药后的最初1/2至1小时最为明显,此时血浆和肾组织中的丙磺舒水平最高。由于丙磺舒对西咪替丁血浆浓度无影响,这种相互作用在这两种化合物的治疗应用中无临床相关性。然而,该研究表明有机阳离子和有机阴离子之间的肾脏相互作用可在人类中发生。这种相互作用的机制及其对其他药物组合的影响正在探索中。